Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Profile Name | HRAS G13R SRC T341M |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
HRAS G13R SRC T341M | thyroid cancer | sensitive | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, Mekinist (trametinib) inhibited growth of a Sprycel (dasatinib)-resistant thyroid cancer cell line harboring HRAS G13R and an acquired SRC T341M mutation in culture (PMID: 27222538). | 27222538 | |
HRAS G13R SRC T341M | thyroid cancer | resistant | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a thyroid cancer cell line harboring HRAS G13R and an acquired SRC T341M mutation demonstrated resistance to Sprycel (dasatinib) in culture (PMID: 27222538). | 27222538 | |
HRAS G13R SRC T341M | thyroid cancer | sensitive | Selumetinib | Preclinical - Cell culture | Actionable | In a preclinical study, Selumetinib (AZD6244) inhibited growth of a Sprycel (dasatinib)-resistant thyroid cancer cell line harboring HRAS G13R and an acquired SRC T341M mutation in culture (PMID: 27222538). | 27222538 |